Milton H. Werner - 01 Apr 2024 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKT	Stock Option (right to buy)	Award	$0	+45,000		$0.000000	45,000	01 Apr 2024	Common Stock	45,000	$2.16	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	One-third of the options will vest and become exercisable on April 1, 2025, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2025, subject to continued employment through each such vesting date.